On the 23rd November this year pharmaceutical giant Eli Lilly announced that the phase II early-intervention Alzheimer’s disease trial for a monoclonal antibody – solanezumab – designed to remove excess beta-amyloid protein from the brain, had failed. The news has caused another round of hand-wringing and head-scratching in the Alzheimer’s research community because it comes […]

from The Evolution and Medicine Review http://ift.tt/2hO0sze